A proprietary, platform-agnostic technology for creating antibody-drug conjugates. It is designed to enhance the effective density of antigens on tumor cells, thereby improving the efficacy of ADCs, especially against tumors that express low levels of the target antigen. The platform's design also allows for multiple mechanisms of tumor cell killing.

• ·Antigen-, antibody-, indication-, and payload-agnostic for broad applicability
• ·Functionally increases tumor antigen density to improve efficacy in challenging tumors
• ·Utilizes backbone antibodies with intrinsic antitumor activity for added cytotoxicity
• ·Optimized pharmacokinetic profile for rapid tumor exposure and faster systemic clearance to potentially reduce side effects